BridgeBio is substantially advanced its development of an novel treatment for cardiac amyloidosis, leveraging the investigational drug. Initial clinical results suggests potential outcomes for patients affected from the https://biotech687300.blogpostie.com/63377161/firm-improves-amyloidosis-therapy-using-the-drug